Anti-COVID-19 Antibodies & Proteins in Development

Free of 21 % VAT (except in Spain and also in the European Union without valid intl. VAT no), delivery costs do not apply.

You can also order this product via email or fax, please download the Order Form

Publisher: La Merie Publishing
Pages: 27
Format: PDF
Product Line: Competitor Analysis
Product Code: LMCA0184
Release Date: April of 2020
Loading...

Anti-COVID-19 Antibodies & Proteins in Development

This Competitive Intelligence report about Anti-COVID-19 Antibodies & Proteins in Development describes the landscape of industry-driven approaches to discover and develop therapeutic antibodies and proteins for treatment of COVID-19 as of April 6, 2020.

COVID-19 is caused by SARS-CoV-2, which belongs to a group of viruses called coronaviruses that attack the respiratory system. There is currently no licensed vaccine, treatment or cure for COVID-19. Since the outbreak of the SARS-CoV-2 pandemia, industry efforts rapidly have initiated work to repurpose existing biologic therapeutics and discover and develop antibody and protein candidates to treat COVID-19 based on a variety of approaches, including

  • Therapeutic Antibodies & Proteins for Immunomodulation of COVID-19
  • Plasma Immunoglobulins for Treatment of COVID-19
  • Biologic Antivirals
  • Recombinant SAR-CoV-2 Neutralizing Antibodies
  • DNA & mRNA anti-SARS-CoV-2 Antibodies

Clinical evaluation of the first repurposed biologics and plasma-derived immunoglobulins has begun and a total at least 34 vaccine approaches to prevent COVID-19 are in the pipeline.

This report includes a compilation of industry-driven projects in research and development of SARS-CoV-2 targeted antibodies and proteins for treatment of COVID-19. Competitor projects are listed in a tabular format providing information on:

  • Drug Codes,
  • Target / Mechanism of Action,
  • Class of Compound,
  • Company,
  • Product Category,
  • Indication,
  • R&D Stage and
  • additional comments with a hyperlink leading to the source of information.

About Competitor Analysis Series:
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies. The information is provided in a tabular format and fully referenced.

Contacts

Custom Support & Sale:

Mon–Fri: 10:00 am –5:00 pm GMT+01